JPRN-jRCT2080225353已完成2 期
A Japanese Phase 2 study of ME-401 in subjects with relapsed or refractory indolent B-cell non-Hodgkin's lymphoma (NHL)
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients with relapsed or refractory B-cell NHL who is categorized into SLL, WM, LPL by WHO classification
- •- Patients who have been histologically confirmed FL Grade 3b transformation from FL to an aggressive lymphoma at least once
- •- Patients with lymphomatous involvement of the central nervous system
- •- Patients with uncontrolled clinically significant illness
- •- Patients with active interstitial lung disease or a history thereof
排除标准
- •- Patients with relapsed or refractory B-cell NHL who is categorized into SLL, WM, LPL by WHO classification
- •- Patients who have been histologically confirmed FL Grade 3b transformation from FL to an aggressive lymphoma at least once
- •- Patients with lymphomatous involvement of the central nervous system
- •- Patients with uncontrolled clinically significant illness
- •- Patients with active interstitial lung disease or a history thereof
研究者
相似试验
已完成
1 期
Study of ME-401 in subjects with relapsed or refractory indolent B-cell non-Hodgkin's lymphoma and roll over study for subjects who have participated in ME-401-004 studyB-cell non-Hodgkin`s lymphomaJPRN-jRCT2080224714Kyowa Kirin Co., Ltd14
进行中（未招募）
2 期
Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)Indolent B-cell Non-Hodgkin's LymphomaNCT04533581Kyowa Kirin Co., Ltd.61
已完成
1 期
Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's LymphomaRelapsed or Refractory Indolent B-cell Non-Hodgkin's LymphomaNCT03985189Kyowa Kirin Co., Ltd.14
已完成
2 期
Japanese phase II study in untreated patients with CD20 positive B-cell non-Hodgkin's lymphoma evaluating safety of 90-minute infusion of rituximab.CD20 positive follicular lymphoma or diffuse large B-cell lymphoma.JPRN-jRCT2080223607ZENYAKU KOGYO CO., LTD.33
未知
1 期
A phase 1/2 study of ONO-4538JPRN-jRCT2080223545ONO PHARMACEUTICAL CO.,LTD.10